Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Sartorius hits new year high after strong quarterly results and several price-target increases

Sartorius shares jumped after the quarterly report, reaching a new year high, driven by strong performance in the lab business and the bioprocess solutions division. Several analysts raised price targets and confirmed or tightened ratings: RBC moved to Outperform and lifted its target from €220 to €330, Jefferies set €307, JPMorgan €295, Barclays €320 and LBBW €305. Analysts attribute the re-ratings to better business, positive currency effects and an expected acceleration of growth through 2027. » More on deraktionaer.de
Sartorius leads MDAX after nine-month figures with optimistic outlook

The German stock market came under pressure due to doubts about the profitability of large AI investments and rising oil prices; the DAX fell 1.07 percent. Sartorius stood out in the MDAX, rising 4.75 percent after nine-month figures that exceeded expectations and a more optimistic outlook for its lab division. At the same time, SAP and Qiagen benefited from quarterly data and takeover rumors, respectively, while technology and industrial stocks performed particularly weakly. » More on finanzen.net
Sartorius lab division grows thanks to bioanalytics and Mattek acquisition

Sartorius recorded lab-division sales of €524 million in the first nine months, supported by a stable consumables business, accelerated customer projects and strong demand for bioanalytics instruments. Currency-adjusted sales before US tariff refunds rose 8.3%; including customer compensations they grew 7.5% on a currency-adjusted basis and 5.9% nominally. The integration of microtissue developer Mattek, acquired in 2025/26, contributed 1.9 percentage points to the growth. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sartorius has already paid €0.73 in dividends. The last payout was in March.

Financials

In the last quarter, Sartorius had revenue of €911.8M and net profit of €65.9M

(EUR)	June 2026	YoY
Revenue	911.8M	3.11%
Gross profit	433.1M	4.06%
Net profit	65.9M	102.77%
EBITDA	281.2M	19.91%

Fundamentals

Metric	Value
Market capitalization	€15.28B
Number of shares	68.39M
52-week high/low	€329.05 - €160.00
Dividend yield	0.32%
Dividends TTM	€0.73
Beta	1.51
P/E ratio	89.18
PEG ratio	1.40
P/B ratio	6.63
P/S ratio	4.75

Company profile

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Name	Sartorius
CEO	Michael Grosse
Headquarters	Göttingen, ni Germany
Website	sartorius.de
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	04/06/1999
Employees	14,042